Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleYahoo Finance· March 24, 2026

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

View original at finance.yahoo.com

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase…

Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The company is gradually expanding into broader non-oncology therapeutic areas such as autoimmune diseases and metabolic disorders
60% confidence
The company is actively advancing cutting-edge modalities including bispecific ADCs, RDCs, iADCs, and DACs
60% confidence
The company has built a robust pipeline of more than 30 drug candidates, with over 10 in the clinical stage
60% confidence
The company will leverage its innovative and differentiated pipeline to deliver high-quality therapeutic solutions for major unmet medical needs worldwide
60% confidence

Cited in these Via News reports

China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →